@article{article, title  = {{Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma}},

 publisher = {{Ovid Technologies (Wolters Kluwer Health)}},

 url = {{https://doi.org/10.1097/cmr.0000000000000193 }},

 year = {{2015}},

 month = {{1}},

 author = {{Latimer NR and Amonkar MM and Stapelkamp C and Sun P}},

 doi = {{10.1097/cmr.0000000000000193}},

 volume = {{25}},

 journal = {{Melanoma Research}},

 issue = {{6}},

 pages = {{528-536}},

 note = {{Accessed on 2025/10/31}}}